Group 2A includes agents that have limited evidence of carcinogenicity in humans but sufficient evidence in experimental animals. This classification suggests a plausible risk of cancer in humans, though direct evidence may be lacking. The assessment is based on a rigorous review of scientific studies and other relevant data.
